Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene ...

Opens in a new tab or window SAN DIEGO -- Children with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) lived significantly longer without disease recurrence when they received the ...

for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Approval was based on results from the ...

Highlights in acute lymphoblastic leukemia (ALL), presented ... BLIN improved outcomes for children with standard-risk B-cell ALL (B-ALL) at average or higher risk for relapse.

Blinatumomab in addition to standard chemotherapy improved pediatric patients with NCI standard-risk B-cell acute lymphoblastic leukemia survival outcomes.

The randomized phase III AALL1731 trial presented at the American Society of Hematology annual meeting showed that adding the ...

HealthDay News — For patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), obecabtagene autoleucel (obe-cel), an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T ...

Tisagenlecleucel is also approved for use in children and young adults with acute lymphoblastic B-cell leukemia. The CAR-T-cell therapies targeting B-cell maturation antigen — ciltacabtagene ...

Tim was diagnosed with B-cell acute Lymphoblastic Leukemia (B-ALL) on August 16th. He said it's been a battle, but one he is determined to win. "I’m still here. The trick is to remain positive ...

Venetoclax is under clinical development by AbbVie and currently in Phase II for Relapsed Acute Myeloid Leukemia.

Acute lymphoblastic leukemia (ALL) is a malignancy of lymphoid blood cells characterized by the immature lymphocytic ...

Venetoclax is under clinical development by AbbVie and currently in Phase II for Refractory Acute Myeloid Leukemia.